Last reviewed · How we verify

Ace Cells Lab Limited — Portfolio Competitive Intelligence Brief

Ace Cells Lab Limited pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ACE Reno ACE Reno marketed ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
  4. Bioprojet · 1 shared drug class
  5. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  6. Children's Hospital of Fudan University · 1 shared drug class
  7. Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
  8. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ace Cells Lab Limited:

Cite this brief

Drug Landscape (2026). Ace Cells Lab Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ace-cells-lab-limited. Accessed 2026-06-10.

Related